Tackling Treatment-Refractory & Drug-Resistant CMV in the Solid Organ Transplantation Setting

Program Overview

Cytomegalovirus (CMV) is often referred to as the “troll of transplantation” because it lurks quietly, waiting to emerge and complicate the clinical course of organ transplant patients. Join our infectious diseases experts, Drs. Humar, Razonable, and Silveira, as well as an experienced patient with CMV for this live-streamed event aimed at “taming the troll.” The panel will discuss guideline-based CMV treatment strategies and how to approach refractory and drug-resistant CMV after solid organ transplantation (SOT), including a new therapeutic option. Prepare to ask your challenging CMV in SOT questions to the panel at the end of the discussion.

Virtual Event

Credit Expired

Target Audience

Transplantation, infectious diseases, nephrology, internal medicine, and pharmacy clinicians who manage patients with refractory or resistant cytomegalovirus (CMV) after solid organ transplantation.

Educational Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Employ current cytomegalovirus (CMV) treatment guidelines for the use of antiviral therapies and management of their adverse effects
  • Identify treatment-refractory and drug-resistant CMV by correctly interpreting antiviral resistance testing results
  • Select transplant patients who will benefit from the efficacy and reduced toxicity of new CMV therapy

Activity Faculty


Atul Humar, MD, MSc, FRCPC, FAST

Professor, Department of Medicine
University of Toronto
R. Fraser Elliott Chair, Transplantation
University Health Network
Director, University of Toronto Transplant Institute
Toronto, Ontario, Canada


​​Raymund R. Razonable, MD, FIDSA, FAST

Professor, Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota, United States


​​Fernanda P. Silveira, MD, MS, FIDSA, FAST

Director, Clinical Operations, Transplant Infectious Diseases
​University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States

Provider Statement

This activity is provided by RMEI Medical Education, LLC

Supporter Statement

Supported by an educational grant from Takeda Pharmaceuticals, U.S.A., Inc.


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources